Bio-Plexus And Broadlane Enter Into Three-Year Agreement For PUNCTUR-GUARD Safety Technology.

Business Editors, Health/Medical Writers

VERNON, Conn. & SAN FRANCISCO--(BUSINESS WIRE)--Oct. 22, 2001

Bio-Plexus, Inc. (OTCBB:BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced that it has entered into a three-year agreement with Broadlane Inc, a leader in providing supply chain management services to the healthcare industry.

The agreement calls for Broadlane to make available to its customers the Bio-Plexus Punctur-Guard(R) line of safety blood collection products including their newest product, the PUNCTUR-GUARD Safety Winged Set.

"Broadlane has been very proactive in addressing safety and providing alternatives for all their customers," said Christopher Zorn, executive vice president of Sales at Bio-Plexus. "This agreement represents a strong statement of the value of the Bio-Plexus Punctur-Guard technology during a time of increased focus and emphasis on safety blood collection products, and specifically, for effective safety winged set alternatives."

This new relationship with Broadlane brings additional support for the launch of the Bio-Plexus' PUNCTUR-GUARD(R) Winged Set for Blood Collection safety needle as well as expansion of their existing safety needle products into Broadlane customer facilities.

"Just as important to hospitals as quality care, is a safe environment for caregivers," said Hank French, of Broadlane's Contracting Services Department. "Our customers selected Bio-Plexus because the high-quality products they produce offer yet another option in sharps safety."

About Broadlane

Through an extensive suite of services, Broadlane delivers comprehensive supply chain management services to the healthcare industry. Those services include group purchasing, procurement strategy consulting, materials management outsourcing, and technology services. Among the companies that focus on improving efficiencies within the healthcare supply chain, only Broadlane offers this full array of services.

Broadlane customers include leading healthcare providers such as Kaiser Permanente, Tenet Healthcare Corporation (NYSE: THC), Universal Health Services (NYSE: UHS), Continuum Health Partners, Community Health Systems (NYSE: CYH), U.S. Oncology (NasdaqNM: USON), IASIS Healthcare, MedCath Inc. (NasdaqNM: MDTH) and others. Broadlane has offices in San Francisco and Oakland, California; Dallas; and New York City. For more information visit www.broadlane.com.

About Bio-Plexus

Bio-Plexus launched the PUNCTUR-GUARD(R) Winged Set for Blood Collection in July 2001. This followed the Company's receipt of 510(k) approval from the Food and Drug Administration in January 2001 and the successful clinical evaluations of the product undertaken by Bio-Plexus since May 2001. Winged sets are steel hollow bore needles with attached tubing used for blood collection. The PUNCTUR-GUARD Winged Set incorporates the same internal blunting technology used in the Company's PUNCTUR-GUARD multi-sample blood collection needle. Upon activation, an inner hollow blunt needle extends beyond the sharp point of the outer needle prior to removal of the device from the patient, thereby eliminating the exposure to sharp, contaminated needles. Current devices require removal of the contaminated sharp needle from the patient before the outer sheath can be moved into place over the contaminated needle.

Bio-Plexus, Inc., designs, develops, manufactures and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD(R), DROP-IT(R), and PUNCTUR-GUARD REVOLUTION(TM) brand names. For independent evaluations of the PUNCTUR-GUARD(R) blood collection needle, refer to the Centers for Disease Control (MMWR, January 1997) and ECRI (Health Devices, June 1998 and October 1999) studies. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis B and C.

"Note; this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995. Forward looking statements are identified by the use of such terminology as "believes," "expects," "may," "should," "anticipates," "plans," "estimates," and "intends," or derivations or negatives thereof or comparable terminology. Accordingly, such statements involve risks (known and unknown) and uncertainties. These risks and uncertainties include the company's ability to timely and fully implement its bankruptcy court confirmed plan of reorganization; the consummation of the private placement financing provided for in the plan; the availability of sufficient capital to fund the company's operations pending consummation of that financing; the continued willingness of the company's customers, vendors and employees to maintain their relationships with the company during this period; the acceptance of the company's products by health care professionals; the company's ability to protect its propriety technology; availability of qualified personnel; changes in, or failure to comply with government regulations; the risks associated with expanding the company's business internationally; and general economic and business conditions. the company undertakes no obligation to update or advise upon any such forward-looking statement.